LENG8

Across TCGA pan-cancer cohorts, LENG8 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated LENG8 data layer compared with 24 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher LENG8 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated LENG8 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, UCEC, and LUAD are the cancer types where LENG8 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.864	0.718	.002	33	view →
UCEC	OS	Median	All	0.854	0.982	.013	18	view →
LUAD	DFS	Tertile	All	0.985	0.848	.011	15	view →
CCRCC	DFS	Tertile	IV	0.794	0.150	.024	14	view →
HNSC	DFS	Quartile	II,III,IV	0.530	0.783	.042	2	view →
GBM	DFS	Median	All	0.409	0.233	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

LENG8–PDAC (DFS)

Open the PDAC breakdown →